<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633226</url>
  </required_header>
  <id_info>
    <org_study_id>V114-036</org_study_id>
    <secondary_id>2020-003181-39</secondary_id>
    <secondary_id>V114-036</secondary_id>
    <nct_id>NCT04633226</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)</brief_title>
  <acronym>PNEU-PED-KOR</acronym>
  <official_title>A Phase 3, Single-Arm, Open-label Clinical Study to Evaluate the Safety and Immunogenicity of 4 Doses of V114 Administered to Healthy Infants in South Korea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety&#xD;
      and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South&#xD;
      Korea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">December 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 solicited injection-site adverse events (AEs)</measure>
    <time_frame>Up to 7 days after any vaccination</time_frame>
    <description>Solicited injection-site AEs consist of swelling, redness, pain or tenderness, and hard lump.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 solicited systemic AEs</measure>
    <time_frame>Up to 7 days after any vaccination</time_frame>
    <description>Solicited systemic AEs consist of irritability, drowsiness, loss of appetite, and hives or welts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with ≥1 vaccine-related serious adverse events (SAEs)</measure>
    <time_frame>Up to approximately 14.5 months</time_frame>
    <description>An SAE is an untoward medical occurrence in a clinical study participant that results in death, is life-threatening, requires/prolongs inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital birth defect, or other important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants discontinuing study therapy due to AE(s)</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>An AE is an untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with anti-pneumococcal polysaccharides (PnPs) serotype-specific immunoglobulin G (IgG) ≥0.35 µg/mL</measure>
    <time_frame>30 days after vaccination 3</time_frame>
    <description>The percentage of participants with IgG threshold values of ≥0.35 µg/mL for the 15 serotypes contained in V114 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) will be reported. The multiplex, electrochemiluminescence (ECL)-based PnECL v2.0 assay will be used to quantify IgG serotype-specific antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean concentrations (GMCs) of anti-PnPs serotype-specific IgG</measure>
    <time_frame>30 days after vaccination 3</time_frame>
    <description>The GMCs of each serotype-specific IgG will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean concentrations (GMCs) of anti-PnPs serotype-specific IgG</measure>
    <time_frame>30 days after vaccination 4</time_frame>
    <description>The GMCs of each serotype-specific IgG will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pneumococcal Disease</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 4 total doses of V114, administered at ~2, 4, 6, and 12-15 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>V114 0.5 mL sterile suspension for intramuscular injection.</description>
    <arm_group_label>V114</arm_group_label>
    <other_name>VAXNEUVANCE™</other_name>
    <other_name>Pneumococcal 15-Valent Conjugate Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  is a healthy South Korean male or female who is 42 to 90 days of age at the time of&#xD;
             signing informed consent&#xD;
&#xD;
          -  has a parent or legally acceptable representative who understands study procedures,&#xD;
             alternative treatments available, and risks involved and voluntarily agrees to&#xD;
             participate by signing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has a history of invasive pneumococcal disease or known history of other culture&#xD;
             positive pneumococcal disease&#xD;
&#xD;
          -  has known hypersensitivity to pneumococcal conjugate vaccine, any licensed pediatric&#xD;
             vaccine to be administered concomitantly, or any diphtheria toxoid-containing vaccine&#xD;
&#xD;
          -  has had a recent febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary&#xD;
             temperature ≥37.8°C [≥100.0°F]) within 72 hours prior to receipt of study vaccine&#xD;
&#xD;
          -  has known or suspected impairment of immunological function&#xD;
&#xD;
          -  has or his/her mother has human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  has or his/her mother has hepatitis B surface antigen-positive test&#xD;
&#xD;
          -  has known or history of functional or anatomic asplenia&#xD;
&#xD;
          -  has a history of autoimmune disease&#xD;
&#xD;
          -  has a history or suspected history of neurological disorder&#xD;
&#xD;
          -  has received a pneumococcal vaccine prior to study entry&#xD;
&#xD;
          -  has received, or is anticipated to need, corticosteroid therapy&#xD;
&#xD;
          -  has received a blood transfusion of immunoglobulin products&#xD;
&#xD;
          -  has participated in another clinical study of an investigational product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeonbuk National University Hospital ( Site 0008)</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeonrabugdo</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital ( Site 0006)</name>
      <address>
        <city>Ansan-si</city>
        <state>Kyonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital ( Site 0011)</name>
      <address>
        <city>Anyang-si</city>
        <state>Kyonggi-do</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital ( Site 0013)</name>
      <address>
        <city>Hwaseong-si</city>
        <state>Kyonggi-do</state>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center CHA University ( Site 0020)</name>
      <address>
        <city>Seongnam si</city>
        <state>Kyonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changwon Fatima Hospital ( Site 0015)</name>
      <address>
        <city>Changwon</city>
        <state>Kyongsangnam-do</state>
        <zip>51394</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital ( Site 0009)</name>
      <address>
        <city>Yangsan-si</city>
        <state>Kyongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital ( Site 0014)</name>
      <address>
        <city>Daegu</city>
        <state>Taegu-Kwangyokshi</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 0012)</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center ( Site 0019)</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital ( Site 0001)</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital ( Site 0017)</name>
      <address>
        <city>Seoul</city>
        <zip>01812</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nowon Eulji Medical Center, Eulji University ( Site 0005)</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0002)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0007)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea ( Site 0003)</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital ( Site 0016)</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Seoul Hospital ( Site 0010)</name>
      <address>
        <city>Seoul</city>
        <zip>07804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital ( Site 0021)</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

